GC Pharma plans to develop what it intends to be the world’s first blood plasma treatment for COVID-19, with a goal to commercialize the product in the latter half of this year.
The South Korean pharma firm is developing a hyperimmune globulin, GC5131A, manufactured from the fractionation of immune proteins from COVID-19...